Eva Balslev

4.0k total citations
123 papers, 2.4k citations indexed

About

Eva Balslev is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Eva Balslev has authored 123 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 60 papers in Cancer Research and 30 papers in Pathology and Forensic Medicine. Recurrent topics in Eva Balslev's work include Breast Cancer Treatment Studies (48 papers), HER2/EGFR in Cancer Research (36 papers) and Breast Lesions and Carcinomas (27 papers). Eva Balslev is often cited by papers focused on Breast Cancer Treatment Studies (48 papers), HER2/EGFR in Cancer Research (36 papers) and Breast Lesions and Carcinomas (27 papers). Eva Balslev collaborates with scholars based in Denmark, United States and Canada. Eva Balslev's co-authors include Bent Ejlertsen, Dorte Nielsen, Niels Kroman, Maj‐Britt Jensen, Ann Knoop, Birgitte Rasmussen, Estrid Høgdall, Kirsten Vang Nielsen, Henning T. Mouridsen and Elisabeth Specht Stovgaard and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eva Balslev

117 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Balslev Denmark 28 1.2k 982 797 347 308 123 2.4k
Yan‐Gao Man United States 28 1.2k 1.0× 1.1k 1.1× 1.3k 1.7× 480 1.4× 382 1.2× 95 3.1k
Panagiota Economopoulou Greece 26 1.4k 1.1× 628 0.6× 891 1.1× 304 0.9× 597 1.9× 105 2.7k
Pornchai O‐charoenrat Thailand 28 1.5k 1.2× 905 0.9× 1.6k 2.0× 136 0.4× 397 1.3× 58 2.9k
Dora Lai‐Wan Kwong Hong Kong 27 750 0.6× 787 0.8× 986 1.2× 168 0.5× 225 0.7× 69 2.1k
Emanuela Bonoldi Italy 23 738 0.6× 499 0.5× 801 1.0× 341 1.0× 292 0.9× 80 1.9k
Huanwen Wu China 30 1.2k 1.0× 640 0.7× 759 1.0× 357 1.0× 566 1.8× 183 2.8k
Elena Guerini‐Rocco Italy 27 1.2k 0.9× 716 0.7× 613 0.8× 449 1.3× 578 1.9× 130 2.3k
Samia Mourah France 33 1.3k 1.0× 431 0.4× 1.5k 1.8× 455 1.3× 280 0.9× 162 3.1k
Evgeny Yakirevich United States 28 846 0.7× 540 0.5× 833 1.0× 283 0.8× 614 2.0× 89 2.3k
Jan P. A. Baak Netherlands 29 782 0.6× 680 0.7× 851 1.1× 455 1.3× 316 1.0× 70 2.5k

Countries citing papers authored by Eva Balslev

Since Specialization
Citations

This map shows the geographic impact of Eva Balslev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Balslev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Balslev more than expected).

Fields of papers citing papers by Eva Balslev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Balslev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Balslev. The network helps show where Eva Balslev may publish in the future.

Co-authorship network of co-authors of Eva Balslev

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Balslev. A scholar is included among the top collaborators of Eva Balslev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Balslev. Eva Balslev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jensen, Maj‐Britt, Eva Balslev, Ann Knoop, et al.. (2024). Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial. Journal of Clinical Oncology. 43(4). 373–380. 3 indexed citations
2.
Nielsen, Dorte, Erik Jakobsen, Sven Tyge Langkjer, et al.. (2023). Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 3130–3130.
3.
Thagaard, Jeppe, Elisabeth Specht Stovgaard, Søren Hauberg, et al.. (2021). Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers. Cancers. 13(12). 3050–3050. 25 indexed citations
4.
Balslev, Eva, et al.. (2021). Targeting the Supply Lines of Cancer – A Possible Strategy for Combating the Disease?. Anticancer Research. 41(6). 2737–2744. 4 indexed citations
5.
Jensen, Steffen Grann, P. E. Thomas, Ib Jarle Christensen, et al.. (2020). Evaluation of analytical accuracy of HER2 status in patients with breast cancer. Apmis. 128(11). 573–582. 9 indexed citations
6.
Jensen, Maj‐Britt, et al.. (2019). Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study. Breast Cancer Research and Treatment. 175(3). 713–719. 10 indexed citations
7.
Christensen, Ib Jarle, Eva Balslev, Ann Knoop, et al.. (2019). Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay. Breast Cancer. 27(2). 266–276. 1 indexed citations
8.
9.
Blaakær, Jan, Torben Steiniche, Estrid Høgdall, et al.. (2018). Evidence of No Association Between Human Papillomavirus and Breast Cancer. Frontiers in Oncology. 8. 209–209. 19 indexed citations
10.
Jensen, Maj‐Britt, et al.. (2017). The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. European Journal of Cancer. 87. 1–9. 16 indexed citations
11.
12.
Jensen, Maj‐Britt, et al.. (2014). Reduced risk of axillary lymphatic spread in triple-negative breast cancer. Breast Cancer Research and Treatment. 149(1). 229–236. 32 indexed citations
13.
Munro, Alison F., Eva Balslev, Christopher Twelves, et al.. (2013). Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?. Breast Cancer Research. 15(2). R31–R31. 3 indexed citations
14.
Balslev, Eva, Anne E. Lykkesfeldt, Niels Kroman, et al.. (2011). Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Breast Cancer Research and Treatment. 128(1). 165–170. 3 indexed citations
15.
Roslind, Anne, et al.. (2008). Subcellular Localization of YKL-40 in Normal and Malignant Epithelial Cells of the Breast. Ultrastructural Pathology. 32(3). 101–106. 3 indexed citations
16.
Bertelsen, Lone S., Lene Mellemkjær, Eva Balslev, & Jørgen H. Olsen. (2008). Benign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients. American Journal of Epidemiology. 168(3). 261–267. 10 indexed citations
17.
18.
Olsen, Karen Ege, Helle Knudsen, Birgitte Rasmussen, et al.. (2004). Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncologica. 43(1). 35–42. 61 indexed citations
19.
Lam, Grace Y., et al.. (2002). Leydig cell tumour – A rare testicular tumour. International Urology and Nephrology. 33(1). 103–105. 12 indexed citations
20.
Fischer, Simon & Eva Balslev. (1989). Vascular protein deposits in temporal arteritis with special reference to failure of histological findings. Apmis. 97(7-12). 1125–1132. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yan‐Gao Man Breakdown of academic impact, for papers by Panagiota Economopoulou Breakdown of academic impact, for papers by Pornchai O‐charoenrat Breakdown of academic impact, for papers by Dora Lai‐Wan Kwong Breakdown of academic impact, for papers by Emanuela Bonoldi Breakdown of academic impact, for papers by Huanwen Wu Breakdown of academic impact, for papers by Elena Guerini‐Rocco Breakdown of academic impact, for papers by Samia Mourah Breakdown of academic impact, for papers by Evgeny Yakirevich Breakdown of academic impact, for papers by Jan P. A. Baak
Rankless by CCL
2026